Company / Current Liabilities
Adaptimmune Therapeutics PLC Current Liabilities History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$64.5M
FY2024
5-year range
$39.1M / $72.8M
FY2020-FY2024
Trend
-11.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 9 years, ranging from $24M in FY2018 to $74M in FY2017.
Based on SEC 10-K filings.
$65M in FY2024 with a 5-year CAGR of +13.4%.
Remained stable around $65M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +1.0%
- 5-Year CAGR
- +13.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +13.4%, indicating consistent growth.
- In FY2024, current liabilities decreased 11.3% year-over-year.
- Peak current liabilities was recorded in FY2017.
- Lowest current liabilities in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $64.5M | -11.3% |
| FY2023 | $72.8M | +12.8% |
| FY2022 | $64.5M | +3.1% |
| FY2021 | $62.5M | +60.1% |
| FY2020 | $39.1M | +13.8% |
| FY2019 | $34.3M | +40.5% |
| FY2018 | $24.4M | -67.1% |
| FY2017 | $74.3M | +84.5% |
| FY2016 | $40.3M | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026